A “dose effect” of GBA mutations on PD phenotype was also described by Thaler et al., with a more severe PD phenotype in patients with GD and PD (GD-PD) as compared to GBA-related PD patients (GBA-PD) and iPD. This evidence concerns the gene GBA1 and Parkinson disease.